Abstract. Recombinant 
patient with a very high antibody titre. Total GH levels were similar to free GH levels in normal subjects. In patients with GH antibodies, total GH levels were high compared with their free levels, but similar to those assayed by conventional RIA. The patient with the highest antibody titre had total GH levels which were the lowest of those observed in the patients with GH antibodies in spite of having the highest GH levels measured by conventional RIA. The antibody in this particular case may have a high capacity and a high affinity. A relatively poor growth rate in this patient may be associated with the finding of undetectable free GH levels. Measurement of plasma free and total GH may be of value in examining GH dynamics and their relation to the clinical effectiveness of GH treatment in patients with GH antibodies.
One of the principal problems of growth hormone therapy to patients with pituitary dwarfism is the attenuation of the growth rate by therapy-induced antibodies (Parker et al. 1964; Prader et (Shizume et al. 1974) . A rec¬ ombinant hGH (methionyl GH) has been shown to be more antigenic than pituitary preparations in spite of its similar clinical effects and lack of side effects (Hanson & Wold 1985; Tyllström et al. 1985; Bierich et al. 1986; Kaplan et al. 1986; Takano et al. 1986 Takano et al. , 1987 . The antigenicity and titre of the anti¬ bodies generated in response to recombinant hGH have been greatly reduced in a later product (S3, Somatrem®) compared with the earlier one (S,), but S3 still raised antibodies in 72% of the patients after 12 months of therapy (Tyllström et al. 1985) . However, only a few cases have been reported in which antibodies definitely interfered with growth (Bierich et (specific activity 30 mCi/mg, 10 000 cpm in 50 µ ) was ex¬ pressed as the percent of total radioactivity (Fig. 1) Grodsky & Forsham (1960) . The precipitate was then dissolved in the buffer used in the RIA kit and assayed without modifica¬ tion (Fig. 1) .
Results

Measurement ofGH antibodies
PEG precipitable fractions were all less than 1% in the plasma samples from 12 normal subjects (Table Table 2 Changes in antibody titres and in the heights of the patients during 1 year of GH therapy are shown in Fig. 4 . Both basal and peak levels were similar to those measured by conventional RIA and free GH in the 3 patients without antibodies. In the 6 patients with antibodies, basal levels were similar to those measured by conventional RIA, and additional increases were observed in 5 pa¬ tients, usually peaking 4 to 6 h after Somatrem in¬ jection. A good correlation was observed between total GH levels and those measured by conven¬ tional RIA (patient No. 9 was withdrawn from the calculation of the correlation, Fig. 5 ). (Fig. 3) . Changes in total GH levels were similar when compared with those measured by conventional RIA after Somatrem in all the pa¬ tients with antibodies with the exception of patient No. 9 (Fig. 2 and 4 
